Sophia Genetics
 Company's logo | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2011 |
| Headquarters | |
Area served | Worldwide |
Key people | |
| Products | Sophia AI platform |
| Services | genomic and radiomic analysis |
Number of employees | 300+ |
| Subsidiaries | Interactive Biosoftware |
| Website | www |
SOPHiA GENETICS is a Swiss biotechnology company with its headquarters in Lausanne and Boston.[1][2] It provides genomic and radiomic analysis for hospitals.[3][4] The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017.[5]
History
Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011. The company is headquartered in Lausanne and Boston[6]
In September 2017, the company introduced an analytical software platform, which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples.[7][8]
In 2018, the company set up its first research and development centre in France and made acquisition of a France-based molecular biology and genetic analytics software development company, Interactive Biosoftware.[9][10]
In 2020, the company appointed Troy Cox, former board of directors member, as its new chairman,[11][12] and Lara Hashimoto as chief business officer.[13]
Funding
In September 2013, as part of a Series A round of funding, Sophia Genetics received $30 million for its medical software platform. The funding round was led by a London-based venture capital firm Balderton Capital with participation from Invoke Capital, and Belgian pharmaceutical entrepreneur Marc Coucke.
In 2014, as part of a Series B round of funding, the company raised $13.75 million from Swisscom and Endeavour Vision.[14]
In December 2015, as part of a Series C round of funding, Sophia Genetics raised $15 million from Omega Pharma founder and healthcare scion Marc Coucke.[15]
In September 2017, as part of a Series D round of funding, the company received $30 million from UK-based VC firm Balderton Capital, 360 Capital Partners, and existing investors including Invoke Capital and Alychlo.[16]
In January 2019, as part of a Series E round of funding, the company raised $77 million. The round was led by Generation Investment Management and included early backers Idinvest Partners, Balderton Capital, and Alychlo.[6][17][18]
Partnership
Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits[19][20]
The company also partners with Illumina and MGI, a subsidiary of BGI Group, to enable their users to access SOPHiA Platform for data analysis and interpretation.[21][22]
References
- ^ Murgia, Madhumita (2015-11-29). "Data-driven medicine: SOPHiA GENETICS becomes largest clinical genomics network". The Daily Telegraph. Retrieved 2019-07-08.
- ^ "Swiss data analytics company SOPHiA GENETICS could be Switzerland's next unicorn". TechCrunch. Retrieved 2019-07-08.
- ^ "An Interview with SOPHiA GENETICS: STS and the CE-IVD Designation". Front Line Genomics. 2019-04-16.
{{cite web}}: CS1 maint: url-status (link) - ^ Gaskell, Adi; Wall, Matthew (2018-04-27). "How knowing your genetic code could lengthen your life". BBC. Retrieved 2019-07-08.
- ^ "The 50 Smartest Companies of 2017 might not be what you think". MIT Technology Review. Retrieved 2019-07-08.
- ^ a b Lomas, Natasha (4 January 2019). "Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its 'data-driven medicine'". TechCrunch.
- ^ "Swiss company sets up US headquarters in Boston - The Boston Globe". The Boston Globe. 24 September 2018.
- ^ Sweeney, Kate (24 September 2018). "Genome analysis ace opens in Boston Massachusetts | Business Weekly | Technology News | Business news | Cambridge and the East of England". Business Weekly.
- ^ Lerivrain, Hélène (25 April 2018). "La biotech suisse Sophia Genetics continue d'investir et s'installe au Pays basque". La Tribune (in French).
- ^ Chavanne, Yannick (18 June 2018). "Sophia Genetics rachète un spécialiste mondial de l'exploration de variations génomiques". ICT Journal (in French).
- ^ Hale, Conor (21 February 2020). "Sophia Genetics taps ex-Foundation Medicine CEO as chairman". FierceBiotech.
- ^ "Sophia Genetics changera de président début mars". AGEFI (in French). 20 February 2020.
- ^ Credi, Mer (8 April 2020). "Sophia Genetics élargit son équipe de direction". AGEFI (in French).
- ^ "Sophia Genetics Raises $13.8M in Private Financing Round". GenomeWeb. 8 July 2014.
- ^ "Europe's leading entrepreneurs leads Series C Round in Sophia Genetics". Venture Lab. 16 December 2015.
- ^ Lomas, Natasha (13 September 2017). "Balderton joins $30M Series D for big data biotech platform play, Sophia Genetics". TechCrunch.
- ^ Wise, James (4 January 2019). "Sophia Genetics announces new $77M funding round". Medium (website).
- ^ O'brien, Chris (4 January 2019). "Swiss startup Sophia Genetics raises $77 million to expand its AI diagnostic platform in the U.S." VentureBeat.
- ^ "IDT, SOPHiA Genetics Broaden Partnership to Clinical-Grade Technologies". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 17 January 2020.
- ^ "Sophia Genetics, Paragon Genomics Team on SARS-CoV-2 Testing". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 26 March 2020.
- ^ "Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx". GenomeWeb.
- ^ "Sophia Genetics to Provide Access to Genomic Analysis Platform to MGI Customers". GenomeWeb.
